Pulling back from the brink
The US healthcare reform bill raises as many questions as it answers for Big Pharma
For the pharmaceutical industry, the bill is a bit of a mixed bag, although the general impression at the moment is that manufacturers will gain more than they lose. At the very least some of the uncertainty affecting the sector has been removed.
With an extra 32 million potential patients entering the market, the number of prescriptions is bound to rise, but this is likely to be offset by the imposition of higher discounts and rebates. And with a number of significant patents due to expire in 2011, a short-term downturn for the industry seems inevitable, although these negative effects should be offset by rising revenues from increased drug consumption by around 2015, according to Datamonitor.
But as drug costs rise, the US government is bound to want to make sure it is getting the best possible value for its money and will increase its involvement in the healthcare sector. While this will be good news for the manufacturers of generic medicines, the authorities will need to try to avoid some of the less palatable aspects of the UK system – trying to define ‘quality of life’, and the notorious ‘postcode prescribing’.
From a European point of view, the US system was patently unfair and long overdue for reform. However imperfect the various healthcare regimes are in the EU, there is at least always a safety net to ensure that every citizen is entitled to receive at least a basic level of service.
It is hard to comprehend the strenuous efforts mounted – both by opposition politicians and the general public – to defend a system that excludes more than 32 million people and where a patient who survives cancer is essentially ruled out of any future treatment by a massive rise in premiums that put them beyond the reach of those on an average income. Shockingly, half of all personal bankruptcies in the US are at least partially due to medical costs.
The reforms may still be flawed, but at least those outside the current system dangling by a thin rope and staring into the abyss have been thrown a lifeline.
Hilary Ayshford
Editor
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026